Saturday 17 October 2026
Export PROK’s income statement to Excel — free account
ProKidney Corp.
PROK Healthcare Biotechnology
ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024. In the quarter to June 2026, revenue fell 32.1%, EPS fell 15.4% and free cash flow fell 28.0%, each against the same quarter a year earlier.
1.33
0.13
−8.90%
Follow PROK
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 9.70 | 5.14 | 1.12 | 1.18 | 0.46 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 10.14 | 14.00 | 14.19 | 4.44 | 7.13 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 87 | 163 | 204 | 231 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 1 | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | (27) | (55) | (147) | (129) | (164) | (151) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (215,701.32) | (16,931.47) | |||||
| Net income | — | 0 | — | — | (27) | (55) | (148) | (135) | (163) | (152) | |||||
| Depreciation | — | — | — | — | 1 | 2 | 3 | 4 | 5 | 7 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | ||||
| Earnings | — | — | — | — | — | (0.09) | (0.23) | (0.57) | (0.62) | (0.52) | |||||
| Cash flow | — | — | — | — | 0.00 | (0.82) | (1.25) | (1.46) | (1.29) | (0.90) | |||||
| Capex | — | — | — | — | 0.00 | (0.08) | (0.03) | (0.55) | (0.30) | 0.02 | |||||
| Free cash flow | — | — | — | — | 0.00 | (0.90) | (1.28) | (2.01) | (1.59) | (0.87) | |||||
| Book value | — | — | — | — | 0.00 | 0.44 | (17.82) | (17.88) | (10.16) | (7.55) | |||||
| Shares, m | — | — | — | — | — | 62 | 62 | 62 | 98 | 134 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 335.98 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 33.98 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 1.24 | (0.26) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (25) | (50) | (77) | (90) | (126) | (120) | ||||
| Capex | — | — | — | — | (5) | (5) | (2) | (34) | (30) | 3 | |||||
| Free cash flow | — | — | — | — | (31) | (55) | (79) | (124) | (156) | (117) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 15 | 494 | 349 | 360 | 250 | ||||
| Total debt | — | — | — | — | — | 1 | 2 | — | — | — | |||||
| Net debt | — | — | — | — | — | (21) | (490) | (363) | (358) | (270) | |||||
| Shareholders’ equity | — | — | — | — | — | 27 | (1,097) | (1,103) | (995) | (1,011) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (273.69) | (38.70) | (7.56) | (14.20) | (17.77) | ||||
| ROIC | — | — | — | — | 0.00 | (541.65) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | 0.00 | 20.20 | 3.22 | 5.83 | 6.88 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
ProKidney Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | $456.8M | — (loss-making) | — (loss-making) | +23.96% (above 0%: growing) | n/m | −10.40% (below 0%: shrinking) | 100.00% | (7,603.42%) | Compare |
| EPRX Eupraxia Pharmaceuticals Inc. | $446.2M | — (loss-making) | — | — | n/m | −56.41% (below 0%: shrinking) | — | 0.00% | Compare |
| MPLT MapLight Therapeutics, Inc. | $445.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | Compare |
| OVID Ovid Therapeutics | $441.4M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| PROK ProKidney Corp. | $439.9M | — (loss-making) | — (loss-making) | −32.13% (below 0%: shrinking) | n/m | −28.03% (below 0%: shrinking) | 100.00% | (32,248.67%) | |
| INDP Indaptus Therapeutics, Inc. | $437.7M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PRTA Prothena Corporation plc | $436.4M | — (loss-making) | 188× | −77.15% (below 0%: shrinking) | n/m | +44.64% (above 0%: growing) | 100.00% | (2,089.21%) | Compare |
| DMAC DiaMedica Therapeutics, Inc. | $433.6M | — (loss-making) | — (loss-making) | — | n/m | −6.75% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PRTCY PureTech Health PLC Sponsored ADR | $424.0M | — (loss-making) | — (loss-making) | −44.60% (below 0%: shrinking) | +66.43% (above 0%: growing) | +19.27% (above 0%: growing) | 2.83% | 0.00% | Compare |
| Median of peers | $439.5M | — | — | −10.32% | — | −8.57% | 51.42% | 0.00% |
ProKidney Corp. (PROK) key facts
- Strength: ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024.
- ProKidney Corp. (PROK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PROK traded at $1.33, a market capitalization of $439.9 million.
- Return on equity was 6.88% and debt-to-equity 0.00.
- Its Altman Z-score is −5.89 (distress zone) for fiscal 2025.